Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Charles Schwab Investment Management Inc. lessened its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 162,398 shares of the biotechnology company’s stock after selling 1,649 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Enanta Pharmaceuticals worth $1,682,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth about $35,000. US Bancorp DE increased its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth about $122,000. Quest Partners LLC boosted its position in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 7,287 shares during the period. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $6.31 on Tuesday. Enanta Pharmaceuticals, Inc. has a 52-week low of $5.84 and a 52-week high of $17.80. The firm has a market capitalization of $133.73 million, a price-to-earnings ratio of -1.10 and a beta of 0.49. The stock has a fifty day moving average of $10.22 and a 200 day moving average of $11.92.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) EPS. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ENTA. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Finally, JMP Securities reissued a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.